Improving HIV vaccine effectiveness by blocking immune suppression

Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacy

NIH-funded research Cincinnati Childrens Hosp Med Ctr · NIH-11014411

This study is looking at ways to make HIV vaccines work better by figuring out how certain immune cells, called natural killer cells, can sometimes hold back the body's immune response, and it’s for anyone interested in improving HIV vaccine effectiveness.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCincinnati Childrens Hosp Med Ctr NIH-funded
Lab location1 site (Cincinnati, United States)
Project IDNIH-11014411 on NIH RePORTER

What this research studies

This research investigates how to enhance the effectiveness of HIV vaccines by addressing the immune suppression caused by natural killer (NK) cells. The study aims to understand the mechanisms by which NK cells inhibit the immune response, particularly the production of neutralizing antibodies and the activation of T cells. By developing strategies to block this suppression, the research seeks to improve the quality and quantity of immune responses triggered by vaccines, ultimately aiming to create a more effective HIV vaccine.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals at risk of HIV infection who may benefit from improved vaccination strategies.

Not a fit: Patients who are already living with HIV and are not seeking vaccination may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of a more effective HIV vaccine, significantly reducing new infections.

How similar studies have performed: Other research has shown promise in enhancing vaccine responses by targeting immune suppression, suggesting that this approach could be effective.

Where this research is happening

Cincinnati, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.